Agios Pharmaceuticals, Inc. · NASDAQ:AGIO
Agios Pharmaceuticals — Q2 2020 Earnings Presentation
19 slides from Agios Pharmaceuticals's earnings presentation, Jul 30, 2020
Slide 1: Second Quarter 2020 Financial Results
Second Quarter 2020 Financial Results July 30, 2020 1
Slide 2: Agios Conference Call Participants
Agios Conference Call Participants TOPIC PARTICIPANT Introductions Holly Manning, Director of Investor Relations Business Update Jackie Fouse, Ph.D., Chief Executive Officer Clinical Development Update Chris Bowden, M.D., Chief Medical Officer Darrin Miles, Senior Vice President, U.S. TIBSOVO® Perfo
Slide 3: Forward Looking Statements
Forward Looking Statements This presentation and various remarks we make during this presentation contain forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Such forward-looking statements include those regarding Agios’ plans, strategies and expect
Slide 4: Agios 2025 Vision: Focused Innovation. Ambitious Development.
AGIOS 2025 VISION: Focused Innovation. Ambitious Development. Transformative Treatments for Patients Across Three Focus Areas. 4 8+ 6+ $ MOLECULES CASH FLOW MEDICINES INDICATIONS IN THE CLINIC POSITIVE 4
Slide 5: Q2 2020 Highlights
Q2 2020 Highlights Rare Genetic Hematologic Solid Tumors Diseases Malignancies • Established clinical proof-of- • TIBSOVO® net sales of $27.6 • Published data from ClarIDHy study concept for mitapivat in sickle million, an increase of 22% from of TIBSOVO® in cholangio in The cell disease Q1 2020 Lan
Slide 6: Clinical Development Updates
Clinical Development Updates Chris Bowden, M.D., Chief Medical Officer 6
Slide 7: Anticipated Upcoming Milestones
• Mitapivat ACTIVATE and ACTIVATE-T topline data in PK deficiency RARE GENETIC DISEASES between YE 2020 and mid-2021 • Finalize pivotal development plan for mitapivat in thalassemia by the end of 2020; initiate a pivotal program in 2021 Anticipated • Finalize pivotal development plan for mitapivat i
Slide 8: PKR Activation Represents Unique Mechanism of Action
PKR Activation Represents Unique Mechanism of Action with Potential to Address Broad Range of Hemolytic Anemias GLYCOLYSIS Glucose Mutant PKR Wildtype PKR Normal Red Cell Pyruvate Kinase Deficiency Other Hemolytic Anemias FBP PEP PEP PEP wtPKR mPKR wtPKR 1,3-DPG 2,3-DPG Pyruvate Pyruvate Pyruvate 3-
Slide 9: Mitapivat Potential First Disease-modifying Therapy for PK Deficiency
Mitapivat has Potential to be First Disease-modifying Therapy for Patients with PK Deficiency Improvements in Hemoglobin and Other Hemolysis Markers Maintained for More Than 3 Years in Responding Patients from DRIVE PK Extension COMPLICATIONS & COMORBIDITIES HIGH RISK SUPPORTIVE REGARDLESS OF OF IRO
Slide 10: Interim Phase 2 Results in Thalassemia
Interim Phase 2 Results in Thalassemia: Activation of wPKR by Mitapivat Improved Hb and Associated Markers of Hemolysis and Erythropoiesis Treatment with mitapivat induced Hb increase of ≥1.0 g/dL in 12 of 13 evaluable patients, including 100% α-thalassemia patients; 7 of 8 evaluable patients achiev
Slide 11: Clinical Proof-of-concept for Mitapivat Established in Sickle Cell Disease
Clinical Proof-of-concept for Mitapivat Established in Sickle Cell Disease 7 of 8 (88%) efficacy evaluable patients experienced a Hb increase, and 5 of 8 (63%) patients achieved a Hb increase of ≥1.0 g/dL from baseline (range 1.0-2.7 g/dL) at doses of 50 mg BID or lower. Treatment with mitapivat was
Slide 12: PKR Activation Has Potential Broad Utility Across Hemolytic Anemias
PKR Activation Has Potential Broad Utility Across Hemolytic Anemias ~18- ~120- ~3-8K PATIENTS IN 23K 135K U.S. & EU PATIENTS IN PATIENTS IN U.S. & EU U.S. & EU Pyruvate Kinase Deficiency β- and α-Thalassemia Sickle Cell Disease Phase 3 enrollment complete; NTD β- and α- Phase 2 enrollment NIH CRADA;
Slide 13: Significant Growth Potential in Malignant Hematology
Significant Growth Potential in Malignant Hematology ~4K <1K PATIENTS IN PATIENTS IN U.S. & EU U.S. IDH1 Mutant Acute Myeloid IDH1 Mutant Myelodysplastic Leukemia (AML) Syndrome (MDS) TIBSOVO® TIBSOVO® U.S. Approval; R/R AML R/R MDS Phase 1 Expansion MAA Under Review 1L Monotherapy U.S. Approval 1L
Slide 14: Four Distinct Solid Tumor Opportunities Across Three Clinical Molecules
Four Distinct Solid Tumor Opportunities Across Three Clinical Molecules ~2-3K ~9K ~9K ~10K PATIENTS IN PATIENTS IN PATIENTS PATIENTS U.S. & EU U.S. & EU IN U.S. IN U.S. IDH1 Mutant IDH Mutant MTAP-Deleted Non- MTAP-Deleted Cholangiocarcinoma Low Grade Glioma Small Cell Lung Cancer Pancreatic Cancer
Slide 15: TIBSOVO Performance Update
TIBSOVO® Performance Update Darrin Miles, Senior Vice President, U.S. Commercial & Global Marketing 15
Slide 16: Q2 Growth Driven by Increased Demand in R/R and Frontline AML
Q2 Growth Driven by Increased Demand in Both R/R and Frontline AML Segments and Expanding Customer Base TIBSOVO® Revenue (in millions) $28 22% Growth In Product Revenue Quarter-over-Quarter $23 $20 $105 – 115M $17 U.S. Net Sales Guidance for 2020 $14 $9 15% Increase In Unique Prescribers Quarter-ove
Slide 17: Second Quarter 2020 Financial Results
Second Quarter 2020 Financial Results Andrew Hirsch, Chief Financial Officer and Head of Corporate Development 17
Slide 18: Second Quarter 2020 Financial Results
Second Quarter 2020 Financial Results Three Months Three Months Statement of Operations Ended 6/30/20 Ended 6/30/19 Total Revenue $37.3M $26.2M Collaboration Revenue 6.4M 9.8M TIBSOVO® Net Sales 27.6M 13.7M Royalty Revenue 3.3M 2.7M Cost of Sales 0.7M 0.3M Research & Development 90.9M 107.4M Expense
Slide 19: Q&A
Q&A 19
Agios Pharmaceuticals — Q2 2020 Earnings Presentation on 6ix